Item 7.01 Regulation FD Disclosure.

On July 25, 2012, Northwest Biotherapeutics, Inc. (the "Company") issued a press release announcing that its partner in Germany, Fraunhofer IZI, has received the official approval and certification from the regional and national regulatory agencies in Germany (including the Paul-Ehrlich-Institut, or PEI - the German equivalent of the U.S. FDA) for the manufacture of the Company's DCVax®-L immune therapy for human patients with Glioblastoma multiforme brain cancer. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

In addition, on July 25, 2012, the Company sent a letter to its stockholders along with a copy of the press release. A copy of the letter to stockholders is included as Exhibit 99.2 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

Exhibit No. Description

99.1 Press Release of Northwest Biotherapeutics, Inc. dated July 25, 2012.

99.2 Letter to Stockholders of Northwest Biotherapeutics, Inc. dated July 25, 2012.